Therapeutic perspectives in bronchial vascular remodeling in COPD.
COPD may be characterized by significant changes in airway mucosal blood vessels, which may contribute to bronchial airway remodeling. The airway wall is more vascularized in COPD patients than in healthy subjects, though this phenomenon is less evident than in asthmatic patients. The vascular mucosal changes in the airways of patients with COPD are strictly linked to the inflammatory processes. The cellular mechanisms responsible for the microvascular changes are still unclear, however, pro-angiogenic factors, such as VEGF, TGF-beta, FGF, and proteolytic enzymes such as MMPs, may play a role. Up to now, the clinical and functional consequences of this phenomenon and the therapeutic approach have been scarcely investigated. Inhaled corticosteroids seem to have positive effects, by reducing the vascular area and growth factor expression. Specific antagonists to VEGF, TGF- beta, FGF, and MMPs could beneficially control chronic airway inflammation and vascular remodeling in COPD as well as slow down the progression of the disease. Several of these growth factor antagonists are being evaluated and some seem to be effective in reducing vascularity, however further studies are required to ascertain whether or not these antagonists may play a role in COPD therapy.